Search results for "vaccination"

showing 10 items of 660 documents

Space-time airborne disease mapping applied to detect specific behaviour of varicella in Valencia, Spain.

2015

Airborne diseases are one of humanity's most feared sicknesses and have regularly caused concern among specialists. Varicella is an airborne disease which usually affects children before the age of 10. Because of its nature, varicella gives rise to interesting spatial, temporal and spatio-temporal patterns. This paper studies spatio-temporal exploratory analysis tools to detect specific behaviour of varicella in the city of Valencia, Spain, from 2008 to 2013. These methods have shown a significant association between the spatial and the temporal component, confirmed by the space-time models applied to the data. High relative risk of varicella is observed in economically disadvantaged region…

MaleHerpesvirus 3 HumanEpidemiologyHealth Toxicology and MutagenesisGeography Planning and Developmentmedicine.disease_causeChickenpoxSpatio-Temporal AnalysisEnvironmental healthmedicineHumansChildChickenpoxIncidenceVaccinationVaricella zoster virusExploratory analysisModels Theoreticalmedicine.diseaseAirborne diseaseVirologyInfectious DiseasesGeographySpainFemaleEpidemiologic MethodsAlgorithmsSpatial and spatio-temporal epidemiology
researchProduct

Recovery of Varicella-Zoster Virus–Specific T Cell Immunity after T Cell–Depleted Allogeneic Transplantation Requires Symptomatic Virus Reactivation

2008

Abstract Reactivated varicella-zoster virus (VZV) infection causes herpes zoster and commonly occurs after allogeneic hematopoietic stem cell transplantation (allo-HSCT). Because VZV-specific T cell immunity is essential to prevent virus reactivation, we developed an interferon-γ enzyme-linked immunosorbent spot (ELISPOT) assay for the sensitive detection of VZV-reactive T cells at the single-cell level ex vivo. We used this assay to monitor the frequency of VZV-reactive T cells in 17 seropositive patients during the first year after T cell–depleted allo-HSCT. The patients did not receive anti-herpesvirus prophylaxis after stem cell engraftment. Independent of the magnitude of transferred d…

MaleHerpesvirus 3 HumanT-Lymphocytesvirusesmedicine.medical_treatmentT cellHerpes zosterHematopoietic stem cell transplantationmedicine.disease_causeLymphocyte DepletionVirusImmunitymedicineHumansTransplantation HomologousImmunity CellularTransplantationintegumentary systembusiness.industryELISPOTVaccinationHematopoietic Stem Cell TransplantationELISPOTVaricella zoster virusvirus diseasesViral VaccinesRecovery of FunctionHematologybiochemical phenomena metabolism and nutritionVirologyTransplantationmedicine.anatomical_structureHematologic NeoplasmsImmunologyVaricella-zoster virusFemaleVirus ActivationInterferon-γStem cellT cell depletionbusinessBiology of Blood and Marrow Transplantation
researchProduct

Cellular immune response of a varicella vaccine following simultaneous DTaP and VZV vaccination.

1999

Abstract Background : Chickenpox and zoster are an important cause of morbidity among children and adults. The ability of a new, thermostable vaccine to induce varicella–zoster-virus (VZV)-specific humoral and cell mediated immunity when given simultaneously with diphtheria–tetanus-acellular pertussis vaccine (DTaP) as a booster dose in the second year of life was investigated. Methods : A new, temperature stable varicella vaccine (OKA-strain, SB-Biologicals, Rixensart, Belgium) was given simultaneously with a booster dose of DTaP vaccine. VZV-specific humoral and cell-mediated immunity was studied in the first 27 out of 232 vaccinated children at 16–28 months of age, from blood samples dra…

MaleHerpesvirus 3 HumanVaricella vaccinevirusesT-LymphocytesImmunization SecondaryBooster dosemedicine.disease_causeAntibodies ViralLymphocyte ActivationChickenpox VaccineInterferon-gammamedicineHumansWhooping coughDiphtheria-Tetanus-Pertussis VaccineImmunization ScheduleImmunity CellularChickenpoxintegumentary systemGeneral VeterinaryGeneral Immunology and Microbiologybusiness.industryTetanusPublic Health Environmental and Occupational HealthVaricella zoster virusvirus diseasesInfantmedicine.diseaseVirologyInterleukin-10VaccinationInfectious DiseasesChild PreschoolImmunoglobulin GImmunologyMolecular MedicinePertussis vaccineFemalebusinessmedicine.drugVaccine
researchProduct

Active hepatitis B vaccination of dialysis patients and medical staff

1984

AbstractActive hepatitis B vaccination of dialysis patients and medical staff. One hundred six patients with terminal renal insufficiency and 29 medical personnel were given three doses of hepatitis B vaccine at an interval of 0, 1, and 6 months (Merck, Sharp and Dohme, West Point, Pennsylvania, part of a joint study no. 649). Chronic hemodialysis patients (N = 99) received 40 µg vaccine (V) i.m. Uremic patients, who were just about to start chronic dialysis treatment (N = 7), were given 40 µg V, and at the first vaccination 3ml hyperimmune globulin (HBIG) in addition. The medical personnel was alternately vaccinated with 20 µg V (N = 8), 40 µg (N = 11), 40 µg V, and 3ml HBIG at the first v…

MaleHyperimmune globulinHepatitis B virusPediatricsmedicine.medical_specialtyHepatitis B vaccinemedicine.medical_treatmentAntibodies ViralRenal DialysisMedical Staff HospitalHumansMedicineHepatitis B VaccinesSeroconversionDialysisbiologybusiness.industryVaccinationImmunization PassiveViral VaccinesHepatitis BHepatitis Bmedicine.diseaseOccupational DiseasesVaccinationTiterImmunizationNephrologybiology.proteinKidney Failure ChronicFemalebusinessKidney International
researchProduct

Impact of universal vaccination against varicella in Italy.

2014

In Italy, the introduction of Universal Varicella Vaccination (UVV) has been decided but postponed, as a national programme, until 2015, when data from Regions which have already implemented it will be available. Starting from 2003, eight Italian Regions (Basilicata, Calabria, Friuli Venezia Giulia, Apulia, Sardinia, Sicily, Tuscany and Veneto) have progressively introduced UVV, in their immunization programme, with different schedules in children aged 13–15 months and 5–6 years, currently a two-dose schedule is adopted by all Regions. In June 2013, an Interregional Group on Varicella Vaccination (IGVV) has been established in order to assess the effectiveness of varicella vaccination with …

MaleImmunization ProgramsHealth PolicyIncidenceimmunization coverageVaccinationUniversal Varicella VaccinationInfantnotificationsadverse events following varicella immunizationVaricellaChickenpox VaccineHospitalizationChickenpoxItalyChild PreschoolHumansFemaleHealth Services ResearchChildhospitalizationsResearch PaperHuman vaccinesimmunotherapeutics
researchProduct

GM-CSF Programs Hematopoietic Stem and Progenitor Cells During Candida albicans Vaccination for Protection Against Reinfection

2021

More mechanistic studies are needed to reveal the hidden details of in vivo-induced trained immunity. Here, using a Candida albicans live vaccine mouse model we show that vaccination protects mice against a secondary infection and increases the number of bone marrow, and especially, splenic trained monocytes. Moreover, vaccination expands and reprograms hematopoietic stem and progenitor cells (HSPCs) early during infection and mobilize them transiently to the spleen to produce trained macrophages. Trained HSPCs are not only primed for myeloid cell production but also reprogramed to produce a greater amount of proinflammatory cytokines in response to a second challenge. Additionally, their a…

MaleMacrophagesImmunologyVaccinationHSPCsGranulocyte-Macrophage Colony-Stimulating FactorGM-CSFmyelopoiesisRC581-607Hematopoietic Stem CellscandidiasisMice Inbred C57BLMicetrained immunityReinfectionCandida albicansImmunology and AllergyAnimalsCytokinesFemaleFungal VaccinesImmunologic diseases. AllergyOriginal ResearchFrontiers in Immunology
researchProduct

Baseline sero-epidemiology of hepatitis B virus infection in children and teenagers in Italy. A survey before mass hepatitis B vaccination

1991

During the period May 1987 to November 1989, the prevalence of hepatitis B virus (HBV) markers was determined by ELISA in serum samples of 7405 (55% male, 45% female) apparently healthy persons 3-19 years of age in Italy. Earlier studies of adults there had shown an intermediate degree of HBV endemicity (hepatitis B surface antigen carrier rate greater than 2%). Persons were selected by systematic cluster sampling in five different geographical areas of Italy. The overall prevalence of hepatitis B surface antigen (HBsAg) was 0.6%. The overall prevalence of at least one marker of HBV was 2.8%; it increased from 1.7% among children 3-5 years of age to 4.5% in teenagers 17-19 years of age (P l…

MaleMicrobiology (medical)HBsAgmedicine.medical_specialtyAdolescentmedicine.disease_causeHepatitis b surface antigenPregnancyEpidemiologyPrevalencemedicineHumansSero epidemiologyChildHepatitis B virusPregnancyHepatitis B Surface Antigensbusiness.industryHepatitis BSerum samplesmedicine.diseaseInfectious DiseasesItalySocioeconomic FactorsHepatitis b vaccinationChild PreschoolImmunologyFemalebusinessDemographyJournal of Infection
researchProduct

Hepatitis B virus infection in native versus immigrant or adopted children in Italy following the compulsory vaccination.

2001

Background: Compulsory vaccination of children against hepatitis B virus (HBV) infection was introduced in Italy in 1991. Patients and Methods: To evaluate the current importance of pediatric HBV infection, we studied 359 HBsAg-positive children admitted to 16 centers in Italy from 1991 to 1998. 185 patients were natives of Italy and 174 (39 immigrants and 135 adopted) came from highly endemic countries (eastern Europe: 60.9%, Asia: 16.7%, Africa: 14.9% and Central and South America: 5.7%). Results: Transaminase levels were moderately altered in both Italian (mean 134 UI/l) and foreign children (mean 168 UI/l). In total, 77% of Italian children and 88% of foreign children tested HBeAg posit…

MaleMicrobiology (medical)Hepatitis B virusmedicine.medical_specialtyHBsAgAdolescentmedicine.disease_causeSerologyHepatitis B; vaccination; ItalyAdoptionEpidemiologymedicineHumansHepatitis B VaccinesChildHBV vaccinationHepatitis B virusHepatitis B Surface AntigensImmunization Programsbusiness.industryIncidence (epidemiology)Infantvirus diseasesGeneral MedicineEmigration and ImmigrationHepatitis BvaccinationHepatitis Bmedicine.diseaseAdopted childrendigestive system diseasesVaccinationInfectious DiseasesItalyHBeAgChild PreschoolImmunologyHepatitis B virus hepatitis; Adopted children; Immigrant; HBV vaccinationHepatitis B virus hepatitisFemalebusinessDemographyImmigrant
researchProduct

Persistence of Bactericidal Antibodies After Infant Serogroup B Meningococcal Immunization and Booster Dose Response at 12, 18 or 24 Months of Age

2016

Background: A serogroup B meningococcal vaccine (4CMenB) is licensed for infant use in countries including Canada, Australia and those of the European Union. Data on serum bactericidal antibody (hSBA) waning and the ideal timing of a "toddler" booster dose are essential to optimize vaccine utilization. Methods: An open-labeled, multicenter phase-2b follow-on European study conducted from 2009 to 2012. Participants previously receiving 4CMenB with routine vaccines at 2, 4 and 6 or 2, 3 and 4 months (246Con and 234Con) or at 2, 4 and 6 months intercalated with routine vaccines (246Int) received a booster dose at 12, 18 or 24 months. 4CMenB-naive "Control" participants aged 12, 18 or 24 months…

MaleMicrobiology (medical)Pediatricsmedicine.medical_specialtypaediatricpersistence of immunityImmunization SecondaryMeningococcal VaccinesMeningococcal vaccineBooster doseMeningitis MeningococcalNeisseria meningitidis Serogroup BPaediatric; Persistence of immunity; Serogroup B meningococcal vaccine; Serum bactericidal activity;Serum bactericidal activityserum bactericidal activity03 medical and health sciences0302 clinical medicine030225 pediatricsOutcome Assessment Health CaremedicineHumansmedia_common.cataloged_instance030212 general & internal medicineToddlerEuropean unionSerogroup B meningococcal vaccineImmunization Schedulemedia_commonMedicine(all)MeningococcalBooster (rocketry)business.industryVaccinationInfantbactericidal antibodiesmedicine.diseaseAntibodies BacterialEuropeVaccinationInfectious DiseasesImmunizationPaediatricChild PreschoolPediatrics Perinatology and Child HealthPersistence of immunityFemaleImmunizationbusinessMeningitisPediatric Infectious Disease Journal
researchProduct

Evaluation of the immunogenicity and reactogenicity of a DTPa-HBV-IPV combination vaccine Co-administered with a hib conjugate vaccine either as a si…

2004

A combined DTPa-HBV-IPV/Hib vaccine containing diphtheria (D), tetanus (T), acellular pertussis (Pa), hepatitis B (HBV) and types 1, 2 and 3 inactivated polioviruses (IPV) extemporaneously mixed with a conjugated Haemophilus influenzae type b (Hib) vaccine (Group 1) was compared to the DTPa-HBV-IPV and Hib vaccines (Group 2) administered separately at 3, 5 and 11 months of age (n = 440). A microneutralization assay was used to detect antibodies against the 3 polio virus types (cut-off 1:8 dil), RIA for anti-HBs antibodies (cut-off 10 mIU/ml) and ELISA for antibodies against all other vaccine antigens (cut-off: 0.1 IU/ml for anti-tetanus and anti-diphtheria antibodies; 5 El.U/ml for antibodi…

MaleMicrobiology (medical)Vaccination scheduleEnzyme-Linked Immunosorbent AssayAntibodies ViralInjections IntramuscularRisk Assessmentcomplex mixturesConjugate vaccineGermanyConfidence IntervalsmedicineHumansHepatitis B VaccinesVaccines CombinedBacterial CapsulesDiphtheria-Tetanus-Pertussis VaccineImmunization ScheduleHaemophilus VaccinesProbabilityImmunity CellularReactogenicityGeneral Immunology and MicrobiologyTetanusbusiness.industryImmunogenicityDiphtheriaPolysaccharides BacterialVaccinationInfantGeneral MedicineHib Conjugate vaccinemedicine.diseaseAntibodies BacterialVirologyHexavalent combination; DTPa-HBV-IPV combination vaccine; Hib Conjugate vaccineVaccinationPoliovirus Vaccine InactivatedInfectious DiseasesItalyHib vaccineHexavalent combinationImmunologyFemalebusinessDTPa-HBV-IPV combination vaccineFollow-Up StudiesScandinavian Journal of Infectious Diseases
researchProduct